OM Pharma
| Company type | Société Anonyme |
|---|---|
| Industry | Biopharmaceutical |
| Founded | Barcelona, (1930) |
| Headquarters | Geneva, Switzerland |
Area served | Worldwide |
Key people |
|
| Products | OM-89 |
| Owner | Etienne Jornod (Executive Chairman & Co‑Owner) |
| Website | www |
OM Pharma is a Swiss multinational biopharmaceutical company headquartered in Geneva.
OM Pharma was established in Barcelona in 1930 and relocated its headquarters to Geneva in 1937 under the leadership of Jean-René Ricard, a French pharmacist. In 2020, the company became part of Optimus Holding, led by Etienne Jornod.[1]
The company specializes in developing and commercializing bacterial lysate-based products designed to help prevent respiratory and urinary tract infections by enhancing the immune system. Its research pipeline includes future applications of lysates.[2]
In 2021, OM Pharma received the Geneva Economy Award.[3]
History
Integration into CSL Vifor/Galenica
In 1970, OM Pharma relocated its main operations to Meyrin, where the company continues to operate. In 2009, it was acquired by Galenica, a part of the Vifor Pharma Group.[4][5][6]
Acquisition by Optimus Holding
In 2020, OM Pharma became an independent entity again following its acquisition by Optimus Holding, led by former Vifor Pharma Executive Chairman Etienne Jornod.[7] As part of the transaction, Optimus Holding committed to investing over CHF 250 million to enhance the company’s manufacturing and research capabilities.[8] Since 2024, Roch Ogier has served as the company’s CEO.[9]
Structure and subsidiaries
OM Pharma employs over 400 people, with its global headquarters and biotech campus located in Meyrin, Geneva, and an affiliate in Villars-sur-Glâne, Fribourg.[10]
The company also operates in Peru through an affiliate in Lima and maintains a sales force in Central America, covering Guatemala, El Salvador, Honduras, Nicaragua, Costa Rica, Panama, and the Dominican Republic.[11][12]
References
- ^ "Etienne Jornod achète une deuxième fois OM Pharma à Genève - Le Temps" (in French). 18 September 2020. ISSN 1423-3967. Retrieved 30 October 2024.
- ^ Ogier, Roch; Kherad, Omar; Balavoine, Michael (22 January 2025). "Le travail de l'industrie pharmaceutique reste largement méconnu". Rev Med Suisse (in Swiss French). 902: 116–118.
- ^ "OM Pharma Wins Geneva Economy Award". PharmExec. 21 September 2021. Retrieved 13 November 2024.
- ^ "Galenica acquiert la société biotech OM Pharma - Le Temps" (in French). 8 September 2009. ISSN 1423-3967. Retrieved 1 November 2024.
- ^ BioAlps, Admin (20 October 2021). "BioAlps | 20 years of innovation | OM Pharma". BioAlps. Retrieved 30 October 2024.
- ^ "économie - L'entreprise compte 65 % de frontaliers parmi ses 200 collaborateurs. OM Pharma, rescapée genevoise de la pharmaceutique, a 80 ans". www.ledauphine.com (in French). 9 November 2017. Retrieved 1 November 2024.
- ^ "Etienne Jornod, président d'OM Pharma à Genève: «Il ne faut pas baisser le prix des médicaments de façon linéaire» - Le Temps" (in French). 13 December 2024. ISSN 1423-3967. Retrieved 18 December 2024.
- ^ PricewaterhouseCoopers. "Vifor Pharma Group announces successful sale of OM Pharma to Optimus Holding Ltd". PwC. Retrieved 30 October 2024.
- ^ "La Gazette du LABORATOIRE - OM Pharma nomme Roch Ogier au poste de CEO". www.gazettelabo.fr. Retrieved 1 November 2024.
- ^ "Redevenue indépendante, OM Pharma vise les Etats-Unis - Le Temps" (in French). 13 December 2024. ISSN 1423-3967. Retrieved 18 December 2024.
- ^ "OM Pharma situa su filial peruana como hub regional para Latinoamérica". PMFarma. Retrieved 30 October 2024.
- ^ GESTIÓN, NOTICIAS (3 May 2023). "Farmacéutica | OM Pharma sitúa hub regional en Perú, las razones detrás y negocios a la vista | ECONOMIA". Gestión (in Spanish). Retrieved 1 November 2024.